Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 11.74 0.51% 0.06
SGMO closed up 0.51 percent on Tuesday, December 11, 2018, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SGMO trend table...

Date Alert Name Type % Chg
Dec 11 Narrow Range Bar Range Contraction 0.00%
Dec 11 NR7 Range Contraction 0.00%
Dec 10 Crossed Above 20 DMA Bullish 0.51%
Dec 7 Fell Below 20 DMA Bearish 3.80%
Dec 7 180 Bearish Setup Bearish Swing Setup 3.80%
Dec 7 Wide Bands Range Expansion 3.80%
Dec 6 Stochastic Sell Signal Bearish -1.59%
Dec 6 20 DMA Support Bullish -1.59%
Dec 6 Wide Bands Range Expansion -1.59%
Dec 6 Overbought Stochastic Strength -1.59%

Older signals for SGMO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.5
52 Week Low 9.0
Average Volume 1,883,024
200-Day Moving Average 16.0182
50-Day Moving Average 12.8082
20-Day Moving Average 11.288
10-Day Moving Average 11.885
Average True Range 0.808
ADX 20.39
+DI 18.0144
-DI 25.1868
Chandelier Exit (Long, 3 ATRs ) 12.106
Chandelier Exit (Short, 3 ATRs ) 11.424
Upper Bollinger Band 12.8461
Lower Bollinger Band 9.7299
Percent B (%b) 0.65
BandWidth 27.606308
MACD Line -0.2455
MACD Signal Line -0.3737
MACD Histogram 0.1283
Fundamentals Value
Market Cap 984.65 Million
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -14.49
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.33
Resistance 3 (R3) 12.33 12.14 12.23
Resistance 2 (R2) 12.14 11.99 12.14 12.19
Resistance 1 (R1) 11.94 11.90 11.85 11.94 12.16
Pivot Point 11.75 11.75 11.70 11.75 11.75
Support 1 (S1) 11.55 11.60 11.46 11.55 11.32
Support 2 (S2) 11.36 11.51 11.36 11.29
Support 3 (S3) 11.16 11.36 11.25
Support 4 (S4) 11.16